For pharma companies, proving that an AI system can produce a useful result is becoming a smaller part of the challenge. Far harder questions emerge when that system has to operate inside research environments, manufacturing processes, quality functions or regulated decision-making.
Who owns an output when operating conditions change? How much evidence is enough before people can rely on it? What happens when relevant information sits across systems that were never designed to work together?
Those questions signal a different stage of adoption. Experimentation can establish possibility; execution has to establish reliability, accountability and value. India’s pharmaceutical sector is beginning to encounter that transition, making the next phase less about finding another promising use case and more about deciding which applications can withstand operational reality.
From pilot success to operating reality
Pilot environments offer something production systems rarely can: control. Teams can work with selected datasets, limited users, fixed objectives, and close technical supervision.
Operational pharma environments are different.
- Pilot conditions: controlled inputs, narrow scope, frequent intervention and a clearly defined test environment.
- Production conditions: changing datasets, multiple users, system interfaces, exceptions, compliance requirements and decisions that carry consequences.
Consider a predictive model used to flag a potential manufacturing deviation. During a pilot, performance can be assessed against a clean historical dataset. Inside production, missing sensor readings, changes in equipment behaviour or a new batch characteristic may alter the quality of its output.
Operational success therefore depends on more than model accuracy. It requires a dependable path from data input to model inference, human review and final action.
That is where many pilots meet their first serious test.
Data quality becomes an execution question
Useful AI depends on information that can be found, understood, connected and trusted. Pharmaceutical organisations may hold substantial volumes of laboratory, manufacturing and quality data while still dealing with fragmented systems, inconsistent definitions and gaps in lineage.
Vyansa Intelligence estimates India’s laboratory information management systems market at USD 110 million in 2025, with the market projected to reach USD 197 million by 2032, representing an 8.68% CAGR during 2026–2032. Regulated pharmaceutical laboratories form part of the market scope, alongside other scientific and testing environments.
Significance goes beyond the market’s size. LIMS can support sample tracking, instrument connectivity, result management, quality-controlled workflows, and interoperability—functions that become increasingly important when analytical data are later used in automated or model-assisted decision processes.
For an AI application to work reliably, its underlying information needs to be:
- Traceable to its source and handling history;
- Structured consistently enough for meaningful comparison;
- Available within the workflow where decisions are made;
- Protected through suitable access and change controls;
- Connected to a clear owner when something goes wrong.
Data lineage matters particularly when an AI-generated recommendation needs to be investigated. A scientist or quality professional should be able to determine which records fed the model, what version of the model produced the output and whether any relevant input changed.
AI readiness, therefore, is partly an information-architecture problem. Model sophistication cannot compensate indefinitely for unreliable inputs.
Validation has to move with the model
Technical performance provides only one part of the evidence required for regulated deployment. Pharmaceutical teams also need to establish whether a model performs appropriately for its intended use, under its intended conditions and at an acceptable level of risk.
FDA and EMA’s January 2026 guidance on good AI practice in drug development places particular emphasis on human-centric design, risk-based approaches, clear context of use, multidisciplinary expertise, data governance, performance assessment and lifecycle management.
Three questions become particularly important before moving beyond experimentation:
- Where will the model be used?
- What decision will its output influence?
- What happens when its performance changes?
Context matters because the consequences of an incorrect output differ sharply across applications. A document-classification system and a model influencing a formulation decision cannot be assessed against identical risk thresholds.
Model behaviour can also change when the underlying data change. New products, different raw-material characteristics, altered process conditions or shifts in patient populations can introduce forms of data drift that were absent during the original pilot.
Consequently, validation cannot end on deployment day. Performance monitoring, change control, version tracking, documented review and defined escalation routes need to become part of the operating model.
Scale needs a business case
Technical teams naturally measure what the pilot can observe: prediction accuracy, processing time, automation rates and user activity. Senior management eventually looks further downstream.
- Did investigation time actually fall?
- Did development cycles become shorter?
- Did production capacity improve?
- Did quality teams spend less time on repetitive review?
Lupin provides one example of a move toward portfolio-level execution. Its FY2025–26 integrated report says more than 250 ideas had progressed toward 25+ high-impact use cases, built on reusable enterprise platforms and reaching more than 15,000 users.
The important lesson is not the number alone. Moving from hundreds of ideas to a smaller group of scaled use cases introduces an investment discipline that most organisations eventually need.
| Pilot metric | Bigger business question |
| Prediction accuracy | Did decision quality improve? |
| Time saved | Where did that capacity go? |
| Tasks automated | Did overall process performance improve? |
| Users onboarded | Is adoption translating into outcomes? |
| Model performance | Can value be sustained over time? |
A useful business case therefore follows a chain:
Model output → workflow change → operational outcome → business result
Without that connection, an AI programme can accumulate technically successful pilots without establishing why they deserve wider investment.
India’s AI ecosystem is moving beyond experimentation
Enterprise deployment also depends on what surrounds individual companies. Evaluation mechanisms, data governance practices and public policy can influence how responsibly emerging applications move into real-world use.
India’s Ministry of Health and Family Welfare launched SAHI and BODH in February 2026. SAHI is intended to guide safe, ethical, evidence-based, and inclusive AI adoption, while BODH provides a platform for benchmarking health AI models against diverse real-world data.
Evaluation becomes more important as AI moves closer to consequential decisions.
For pharmaceutical organisations, that principle has practical relevance. Internal benchmarking can reveal where a model performs well, where it produces false positives or negatives, and whether its results remain stable across different datasets or operating conditions.
External frameworks will not remove the need for enterprise-level controls. They can, however, help shift AI adoption away from informal experimentation toward evidence-based deployment.
People still sit inside the system
Pharma AI will not operate in isolation from scientific judgement. Even when software generates predictions, recommendations or ranked options, someone still has to determine whether the output makes sense in the physical and regulatory environment where it will be used.
Express Pharma’s recent coverage of AI-driven Quality by Design offers a useful illustration. Its workflow combines Design of Experiments data, artificial neural-network modelling and targeted experimental validation, rather than treating model output as a substitute for laboratory evidence.
That relationship can be viewed as a simple decision chain:
Historical/experimental data → model prediction → scientific review → targeted testing → decision
Human involvement becomes particularly important when model output conflicts with observed behaviour. A formulation may perform differently during scale-up because of raw-material variability, process conditions, or interactions that were not adequately represented in historical training data. In such cases, scientific experience becomes part of the control mechanism rather than an obstacle to automation.
Execution will therefore require more than AI specialists. Scientists, QA teams, regulatory professionals, data specialists and business owners all need clarity around where AI supports judgement and where human judgement remains decisive.
What comes after the pilot?
Five questions can help determine whether an initiative deserves to move into production.
Is the use case important enough to scale?
Technical novelty should not outweigh operational relevance. Problems with clear business or scientific consequences deserve priority over applications that generate impressive demonstrations but change little.
Is the data fit for purpose?
Historical data may be plentiful yet inconsistent. Missing values, shifting definitions, unstructured records, and weak traceability can become much more expensive problems once a model depends on them at scale.
What evidence is required?
Validation needs to reflect intended use and associated risk. Evidence requirements should be established before deployment rather than added after an operational problem exposes a gap.
Who owns the decision?
Human-in-the-loop does not mean placing a person somewhere near a screen. Responsibility needs to be explicit: who reviews the output, who can override it, who records the rationale and who investigates an unexpected result?
What happens after launch?
Production deployment should trigger monitoring rather than end it. Changes in data, workflows, model versions and performance can all alter risk over time.
Execution becomes the real test
India’s pharmaceutical industry no longer needs to debate whether AI can generate useful predictions or automate selected tasks. Evidence from research, regulation and industry practice increasingly points toward real adoption across parts of the pharmaceutical value chain.
The harder question concerns endurance.
Can an application remain useful when data become messy, workflows change, scientists challenge its output, regulators ask how it was validated, and management wants evidence of business value?
The next important AI milestone for Indian pharma may therefore be far less visible than a new pilot. It may be the point at which a useful system becomes dependable enough to live inside a real pharmaceutical workflow—and remains trustworthy as that workflow evolves.